Rentschler Biopharma Announces Enhanced Collaboration with Summit Pharmaceuticals International Corporation to Expand Japanese Operation-Base


Company also announces participation in BioJapan 2019, one of Asia’s largest partnering events for the global biotechnology industry, October 9-11, 2019 in Pacifico Yokohama


GERMANY AND MILFORD, MA, USA – EQS Newswire – October 4, 2019 – Rentschler Biopharma SE, a world-class contract development and
manufacturing organization (CDMO) for biopharmaceuticals, today reported
that it will further enhance and develop the existing collaboration in Japan with
Summit Pharmaceuticals International Corporation (SPI), a wholly owned subsidiary
of Sumitomo Corporation. Through strong collaboration with SPI, Rentschler
Biopharma has secured new contracts with Japanese pharmaceutical companies. SPI
and Rentschler Biopharma are working together with Japanese clients to outline
projects from early clinical stage up to commercial launch and ensure optimal
service. Japan is one of the largest biopharmaceutical markets
in the world and is an important area of growth for Rentschler Biopharma.


Dr. Frank Mathias, CEO of Rentschler Biopharma,
noted: “Our relationship with SPI has been highly productive and fruitful and
we have been impressed by their strong network and extensive experience in
contract manufacturing and supply. Japanese pharmaceutical companies are playing
an important and expanding role in the global healthcare market, and we are
delighted to be continuing this productive collaboration as we grow our client
base in Japan.”


Federico Pollano, Senior Vice President
Business Development of Rentschler Biopharma, added: “We are pleased to be
expanding our business with Japanese pharmaceutical companies who value
Rentschler Biopharma for our excellent services, outstanding quality and
extensive track-record. We very much look forward to working together with SPI to
provide clients with the best possible advice and assistance from the start of
clinical trials to commercial launch.”


Rentschler Biopharma also announced its
presence at BioJapan 2019, which is being held October
9-11, 2019 in Pacifico Yokohama. The Company is a bronze sponsor of this
important partnering event. Federico Pollano will
give a presentation, titled “Tailormade one-stop-shop solutions for
development and production of biopharmaceuticals”,
on Wednesday, October 9,
11:30-12:00 at the Exhibitor’s Stage. Dr. Frank Mathias, Federico Pollano and
his Business Development team, which includes SPI, will be available to meet at
Rentschler Biopharma’s booth (#D-48).


is the world’s third largest pharmaceuticals market, which is forecast to reach
$89 to $93 billion by 2023. The country is expected to continue dominating this
corner of the global market[i]. There
are over 100 domestic pharmaceutical companies in Japan, with many of the
mid-sized and larger-sized firms in recent years developing drug candidates
with innovative and new modalities, such as biologics and gene and cell
therapies, for markets worldwide. This is increasing the involvement of
Japanese pharmaceutical companies in biopharmaceutical enterprises. Japan has
also seen an increase in biopharmaceutical start-ups, which is further driving
the industry’s growth.


[i] The Global Use of Medicine in
2019 and Outlook to 2023, JANUARY 2019, IQVIATM INSTITUTE.

About Rentschler Biopharma SE

Rentschler Biopharma is a leading contract development
and manufacturing organization (CDMO), focused exclusively on
client projects. From its headquarters in Laupheim, Germany, and its site in
Milford, MA, USA, Rentschler Biopharma offers process development and manufacturing
of biopharmaceuticals as well as related consulting activities, including
project management and regulatory support. Rentschler Biopharma’s high quality
is proven by its long-standing experience and excellence as a solution partner
for its clients. A high-level quality management system, a well-established
operational excellence philosophy and advanced technologies ensure product
quality and productivity at each development and manufacturing step. In order
to offer optimal solutions across the entire value chain, the Company has
entered into a strategic alliance with Leukocare AG for formulation development
and with Rentschler Fill Solutions GmbH for fill & finish services. Rentschler
Biopharma is a family-owned company with more than 850 employees. For further
information, please visit